Program
HSK39004
A development code. Also written as “HSK39004 Inhalation Suspension”, “HSK39004 Dry Powder Inhaler-0.75mg” and “HSK39004 Dry Powder Inhaler -0.75mg BID”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 97 open or running | phase 3since May 7, 2026 | Dec 31, 2024 | Jun 11, 2027phase 3 · NCT07658339 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 31, 2024First study: phase 1 study in Healthy DonorsFirst studyNCT06905847 · 63 enrolled · China
- May 6, 2025Phase 1 study in Healthy VolunteersNCT06971198 · 26 enrolled · China
- Jul 31, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07108699 · 180 enrolled · China
- Aug 18, 20252 phase 2 studiesNCT07140328, NCT07331402
- Feb 13, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07425210 · 300 planned · China
- May 7, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07583849 · 376 planned · China
- Jun 3, 20262 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT07658339, NCT07634367
Ahead
- Jun 11, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07658339
- Jul 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07425210
- Sep 30, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07583849
- Dec 24, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07634367
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07658339Pulmonary Disease, Chronic Obstructive · China | 3 | Not yet recruiting | Jun 11, 2027 | 387 |
| NCT07634367Pulmonary Disease, Chronic Obstructive · China | 3 | Not yet recruiting | Dec 24, 2027 | 300 |
| NCT07583849Pulmonary Disease, Chronic Obstructive · China | 3 | Recruiting | Sep 30, 2027 | 376 |
| NCT07425210Pulmonary Disease, Chronic Obstructive · China | 2 | Not yet recruiting | Jul 2027 | 300 |
| NCT07331402COPD Patients · China | 2 | Active, not recruiting | Dec 30, 2025 | 12 |
| NCT07140328Pulmonary Disease, Chronic Obstructive · China | 2 | Recruiting | Jul 10, 2025 | 50 |
| NCT07108699Pulmonary Disease, Chronic Obstructive · China | 2 | Active, not recruiting | Aug 30, 2026 | 180 |
| NCT06971198Healthy Volunteers · China | 1 | Completed | Mar 28, 2025 | 26 |
| NCT06905847Healthy Donors · China | 1 | Completed | Jan 13, 2025 | 63 |
How it is read
Names in the registry
- “HSK39004 Inhalation Suspension”, 2 entries
- “HSK39004 Dry Powder Inhaler-0.75mg”, 2 entries
- “HSK39004 Dry Powder Inhaler -0.75mg BID”, 2 entries
- “HSK39004 Dry Powder Inhaler -1.5mg BID”, 1 entry
- “HSK39004 Inhalation Suspension -3mg BID”, 1 entry
Codes read as this program: HSK39004.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.